Please login to the form below

Not currently logged in
Email:
Password:

alemtuzumab

This page shows the latest alemtuzumab news and features for those working in and with pharma, biotech and healthcare.

After some big setbacks, Sanofi talks up its R&D portfolio

After some big setbacks, Sanofi talks up its R&D portfolio

It also has high hopes for alemtuzumab in primary progressive MS, Regeneron-partnered cemiplimab for first-line non-small cell lung cancer and SAR425899, a GLP-1/GCR dual agonist that

Latest news

More from news
Approximately 7 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics